A phase II study of S-1 plus irinotecan and oxaliplatin in heavily-treated patients with metastatic colorectal cancer

By Kim Sun   Hong Yong   Kim Byung   Park Ji   Choi Hyo   Jeong Seung-Yong   Kim Dae   Hong Chang   Sohn Dae   Jung Kyung  

Investigational New Drugs, Vol. 27, Iss. 3, 2009-06 ,pp. : 269-274

Springer Publishing Company

Access to resources Recommend Favorite

A phase II randomized study of cetuximab and bevacizumab alone or in combination with gemcitabine as first-line therapy for metastatic pancreatic adenocarcinoma

By Ko Andrew  

Investigational New Drugs, Vol. 30, Iss. 4, 2012-08 ,pp. : 1597-1606

Springer Publishing Company

Access to resources Recommend Favorite

Multicenter, randomized phase II trial of bevacizumab plus folinic acid, fluorouracil, gemcitabine (FFG) versus bevacizumab plus folinic acid, fluorouracil, oxaliplatin (FOLFOX4) as first-line therapy for patients with advanced colorectal cancer

By Madajewicz Stefan  

Investigational New Drugs, Vol. 30, Iss. 2, 2012-04 ,pp. : 772-778

Springer Publishing Company

Access to resources Recommend Favorite

Bevacizumab: In First-Line Treatment of Metastatic Breast Cancer

By Scott Lesley J.  

Drugs, Vol. 67, Iss. 12, 2007-01 ,pp. : 1793-1799

Adis International

Access to resources Recommend Favorite

First-Line Treatment Strategies for Elderly Patients with Metastatic Colorectal Cancer

By Meulenbeld Hielke J.   Creemers Geert-Jan  

Drugs & Aging, Vol. 24, Iss. 3, 2007-01 ,pp. : 223-238

Adis International

Access to resources Recommend Favorite